Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of “Moderate Buy” from Analysts

Abeona Therapeutics Inc. (NASDAQ:ABEO) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $19.00.

A number of research analysts have recently issued reports on ABEO shares. Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $4.45 on Friday. The company has a market cap of $253.87 million, a PE ratio of 4.32 and a beta of 1.13. The firm’s 50 day moving average price is $5.07 and its 200-day moving average price is $5.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.53 and a current ratio of 6.93. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.65 million. Sell-side analysts forecast that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

More Abeona Therapeutics News

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $20.00 price target on ABEO, highlighting upside in the firm’s longer-term view despite near-term headwinds. HC Wainwright Reiterates Buy
• Positive Sentiment: Abeona announced tightened shareholder meeting and governance rules (Third Amended and Restated provisions), which can reduce activist/governance uncertainty and may be viewed favorably by longer-term investors. Governance Update
• Neutral Sentiment: Market consensus coverage shows a “Moderate Buy” view from brokerages — supportive but not unanimous; useful context for sentiment but not a catalyst by itself. Consensus Rating
• Neutral Sentiment: Reported short-interest data showed effectively zero reported short interest in the most recent snapshot, so short-covering is unlikely to be driving intraday moves. (Internal data summary)
• Negative Sentiment: HC Wainwright materially lowered near-term EPS forecasts across 2026 quarters and reduced FY2026 from about ($0.97) to ($1.14), signaling weaker near-term profitability/revenue expectations — a key driver of the stock’s downward pressure. Analyst Estimate Cuts
• Negative Sentiment: Multiple quarterly EPS cuts for 2026 and early‑2027 (Q1–Q3 2026 and Q2 2026 revisions were notable) increase uncertainty about near-term operating performance and could delay any valuation rerating despite the $20 target. Estimate Details

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Christine Berni Silverstein sold 20,070 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total value of $102,156.30. Following the completion of the sale, the director directly owned 137,722 shares in the company, valued at $701,004.98. This trade represents a 12.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joseph Walter Vazzano sold 18,666 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total transaction of $99,489.78. Following the completion of the sale, the chief financial officer owned 568,560 shares of the company’s stock, valued at approximately $3,030,424.80. This trade represents a 3.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 209,605 shares of company stock worth $1,101,300. 6.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Large investors have recently made changes to their positions in the business. Boone Capital Management LLC acquired a new position in shares of Abeona Therapeutics in the second quarter valued at about $7,126,000. AWM Investment Company Inc. acquired a new stake in shares of Abeona Therapeutics during the second quarter worth about $2,670,000. Squarepoint Ops LLC boosted its position in Abeona Therapeutics by 274.2% in the second quarter. Squarepoint Ops LLC now owns 141,978 shares of the biopharmaceutical company’s stock valued at $806,000 after buying an additional 104,037 shares during the last quarter. Diametric Capital LP increased its holdings in Abeona Therapeutics by 637.8% in the 2nd quarter. Diametric Capital LP now owns 138,363 shares of the biopharmaceutical company’s stock worth $786,000 after buying an additional 119,609 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Abeona Therapeutics during the 2nd quarter worth approximately $63,000. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.